Glenmede Trust Co. NA Has $24.59 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Glenmede Trust Co. NA raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,605 shares of the biotechnology company’s stock after purchasing an additional 4,145 shares during the period. Glenmede Trust Co. NA’s holdings in United Therapeutics were worth $24,585,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. ClariVest Asset Management LLC increased its stake in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the last quarter. V Square Quantitative Management LLC acquired a new stake in United Therapeutics in the second quarter valued at about $30,000. Innealta Capital LLC bought a new position in United Therapeutics in the second quarter valued at about $33,000. USA Financial Formulas acquired a new position in United Therapeutics during the third quarter worth about $33,000. Finally, Brooklyn Investment Group bought a new position in shares of United Therapeutics in the third quarter worth about $33,000. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CFO James Edgemond sold 7,802 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the completion of the sale, the chief financial officer now owns 3,210 shares in the company, valued at $1,108,766.10. The trade was a 70.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Christopher Causey sold 510 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $376.63, for a total transaction of $192,081.30. Following the sale, the director now owns 3,675 shares of the company’s stock, valued at $1,384,115.25. This trade represents a 12.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 127,227 shares of company stock valued at $47,398,820 over the last ninety days. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

Shares of UTHR stock opened at $378.13 on Thursday. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The business’s 50 day simple moving average is $366.18 and its 200 day simple moving average is $333.84. The stock has a market capitalization of $16.88 billion, a PE ratio of 16.61, a PEG ratio of 1.07 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.38 EPS. As a group, research analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analyst Ratings Changes

UTHR has been the subject of a number of research analyst reports. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. The Goldman Sachs Group upped their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. Wells Fargo & Company raised their price objective on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, Argus increased their target price on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.